Contact us
Answers to our most commonly asked questions
While on May 7th, 2025, the Company announced entering into an agreement with Shionogi & Co., Ltd. to transfer the pharmaceutical business and our stake in TORII PHARMACEUTICAL CO., LTD.(''Torii''), a consolidated subsidiary of JT, the JT Group's performance and initiatives described on this page include those associated with the pharmaceutical business and Torii.
Please see the press releases on our website for the details.
As announced on September 1, 2025, the transfer of Torii shares has been completed. Please see the press release on our website for the details.
Select category and topic
If you would like to make an inquiry related to the media relations or to the investor relations team, please click the below button. Please note that our media relations or investor relations office may not respond concerning career opportunities or other general inquiries.
Telephone: +81-3-6636-2914
Post: Media & Investor Relations Division Japan Tobacco Inc.
1-1, Toranomon 4-chome, Minato-ku Tokyo 105-6927 JAPAN
If you are our business partner and would like to report a concern related to the following, please click the below button.
- Actions taken by the JT Group or its employees that violate or may violate or might vilate the JT Group Code of Conduct.
- Suspected or confirmed serious violations of the JT Group Supplier Standards.
- ※ Please note that this form is not intended as a method of contact regarding potential business partnerships.
If your inquiry is related to our international tobacco business (excluding Japan or China), and not related to investor relations, please visit the Japan Tobacco International website below.
If you have any other general questions/comments or an inquiry related to JT's activities in sustainability, please click the below button. We would like to hear from you.